(0.36%) 5 118.42 points
(0.28%) 38 345 points
(0.47%) 16 003 points
(-0.51%) $83.42
(2.34%) $1.968
(-0.14%) $2 344.00
(-0.19%) $27.48
(2.65%) $946.55
(0.04%) $0.935
(-0.05%) $11.02
(-0.24%) $0.798
(1.63%) $93.37
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 3.01%
@ $27.58
发出时间: 15 Feb 2024 @ 02:11
回报率: 2.37%
上一信号: Feb 14 - 04:32
上一信号:
回报率: 4.31 %
Live Chart Being Loaded With Signals
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC...
Stats | |
---|---|
今日成交量 | 36 403.00 |
平均成交量 | 555 475 |
市值 | 18.46B |
EPS | $0 ( 2024-02-28 ) |
下一个收益日期 | ( $0.160 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 29.72 |
ATR14 | $0.0120 (0.04%) |
音量 相关性
Genmab A/S 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Genmab A/S 相关性 - 货币/商品
Genmab A/S 财务报表
Annual | 2023 |
营收: | $16.47B |
毛利润: | $15.92B (96.64 %) |
EPS: | $66.64 |
FY | 2023 |
营收: | $16.47B |
毛利润: | $15.92B (96.64 %) |
EPS: | $66.64 |
FY | 2022 |
营收: | $14.60B |
毛利润: | $14.60B (100.00 %) |
EPS: | $83.38 |
FY | 2021 |
营收: | $8.48B |
毛利润: | $0.00 (0.00 %) |
EPS: | $4.60 |
Financial Reports:
No articles found.
Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。